D.C. appeals court sides with HHS in 340B drug discount program rebate challenge

fiercehealthcare - The ruling upheld a previous decision that pharma companies cannot impose rebates without HHS Secretary approval.

AI Summary: The D.C. appeals court sided with HHS in a legal challenge over 340B drug discount rebates, affirming federal authority over the program’s rebate models. The ruling preserves HHS policy changes that influence pricing and hospital participation, potentially reshaping pharmacy discounts and provider finances nationwide.

• Appeals court and federal rulings cement HHS 340B authority (3)
• CMS reimbursement shakeup: winners, losers and litigation fallout (3)
• HRSA’s revised 340B rebate pilot and oversight push (3)

Appeals court and federal rulings cement HHS 340B authority

CMS reimbursement shakeup: winners, losers and litigation fallout

HRSA’s revised 340B rebate pilot and oversight push